On its third-quarter 2026 earnings call, held on Oct. 29, 2026, Supernus (NASDAQ:SUPN) announced that combined revenues for its key growth products rose 43% year over year. For long-term investors, sustained volume gains across core treatments demonstrate expanding market adoption and commercial execution.
Three takeaways from management highlight the strategic priorities for the business.
1. Commercial Growth Products Expanded Revenue by 43%
Supernus relies on its commercial growth lineup, including attention-deficit/hyperactivity disorder (ADHD) treatment Qelbree and postpartum depression medication ZURZUVAE, to drive top-line expansion as legacy treatments mature. Generating higher revenue across these central nervous system therapies validates long-term patient demand and justifies ongoing sales force investments.
For the third quarter of 2026, combined revenues of our growth products, Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI increased by 43% compared to the same period last year.
— Jack Khattar, Chief Executive Officer
2. The Indivior Merger Unlocks $125 Million in Cost Synergies
Combining operations with Indivior Pharmaceuticals expands the commercial footprint across addiction and psychiatry while streamlining shared operations. Management targets $125 million in annual cost synergies, defined as operational savings from combining corporate and sales infrastructure, to enhance future profitability.
Integration planning has been underway, and we remain confident in capturing the $125 million of expected annual cost synergies that we previously discussed.
— Jack Khattar, Chief Executive Officer
3. Federal Exclusivity and Dual Supply May Stabilize ONAPGO Growth
Parkinson’s disease treatment ONAPGO received seven years of orphan drug exclusivity, a regulatory protection for specialized therapies, from the U.S. Food and Drug Administration (FDA). Securing intellectual protection and adding a second manufacturing source is expected to resolve prior supply bottlenecks to support steady prescription intake.
As we announced last week, the FDA has recognized seven years of orphan drug exclusivity for ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
— Jack Khattar, Chief Executive Officer
Looking Ahead
Commercial momentum is building across key treatments, and management is not hiding its satisfaction. Combining 11 differentiated medicines creates scale, while integration planning focuses on pricing discipline and operational execution.